ArticleCancers2021
Value of Combined PET Imaging with [
Article in Cancers, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Investigating the significance of SPECT/CT-SUV for monitoringBMC medical imaging · 2025Pooled it
- PSMA PET Imaging in the Management of Patients with Metastatic Castration-Resistant Prostate Cancer Treated with Radioligand Therapy.Targeted oncology · 2025Review
- Revolutionizing Prostate Cancer Detection: The Role of Approved PSMA-PET Imaging Agents.Pharmaceuticals (Basel, Switzerland) · 2025Review
- Added Value of Whole-Body Diffusion-Weighted Imaging in Patients Undergoing Prostate-Specific Membrane Antigen Positron Emission Tomography.Journal of clinical medicine · 2025Article
- [Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2024Article
- Article
- Prognostic Role of PSMA-Targeted Imaging in Metastatic Castration-Resistant Prostate Cancer: An Overview.Biomedicines · 2024Review
- Imaging and therapy in prostate cancer using prostate specific membrane antigen radioligands.The British journal of radiology · 2024Review
- Dual FDG/PSMA PET imaging to predict lesion-based progression of mCRPC during PSMA-RLT.Scientific reports · 2024Article
- Treatment response assessment in mCRPC: is PSMA-PET/CT going to take the lead?Therapeutic advances in medical oncology · 2024Review
- PET/CT in Prostate Cancer.Cancers · 2023Article
- PSMA PET Tumor-to-Salivary Gland Ratio to Predict Response to [Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2023Article
- Baseline [Cancers · 2023Article
- Change of glucometabolic activity per PSMA expression predicts survival in mCRPC patients non-responding to PSMA radioligand therapy: introducing a novel dual imaging biomarker.Frontiers in medicine · 2023Article
- The VISION Forward: Recognition and Implication of PSMA-/Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2022Article
- Early molecular imaging response assessment based on determination of total viable tumor burden in [European journal of nuclear medicine and molecular imaging · 2022Article
- Current role of prostate-specific membrane antigen-based imaging and radioligand therapy in castration-resistant prostate cancer.Frontiers in cell and developmental biology · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Despite the promising results of prostate-specific membrane antigen (PSMA)-targeted radioligand therapy (RLT) in metastatic castration-resistant prostate cancer (mCRPC), some patients show worsening disease during PSMA-RLT. We investigated the value of combined [
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.